Yuji Shimamoto

1.0k total citations
19 papers, 947 citations indexed

About

Yuji Shimamoto is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yuji Shimamoto has authored 19 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yuji Shimamoto's work include Colorectal Cancer Treatments and Studies (11 papers), Biochemical and Molecular Research (8 papers) and Cancer Treatment and Pharmacology (6 papers). Yuji Shimamoto is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Biochemical and Molecular Research (8 papers) and Cancer Treatment and Pharmacology (6 papers). Yuji Shimamoto collaborates with scholars based in Japan, Spain and South Africa. Yuji Shimamoto's co-authors include Masakazu Fukushima, Tetsuhiko Shirasaka, Hideyuki Ohshimo, Akira Matsuda, Hiroko Saito, Takuma Sasaki, Junji Uchida, Toshiyuki Kato, Teiji Takechi and Hiromi Kazuno and has published in prestigious journals such as Journal of Medicinal Chemistry, Cancer Chemotherapy and Pharmacology and International Journal of Oncology.

In The Last Decade

Yuji Shimamoto

19 papers receiving 928 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuji Shimamoto Japan 14 584 413 346 160 77 19 947
C.J.A. van Moorsel Netherlands 14 644 1.1× 333 0.8× 445 1.3× 157 1.0× 141 1.8× 16 1.1k
Daphne Voorn Netherlands 16 539 0.9× 213 0.5× 389 1.1× 108 0.7× 136 1.8× 21 911
Fumio Nakagawa Japan 20 682 1.2× 299 0.7× 381 1.1× 150 0.9× 118 1.5× 61 1.2k
Hoo G. Chun United States 15 440 0.8× 210 0.5× 304 0.9× 154 1.0× 59 0.8× 31 821
Giovanni Codacci-Pisanelli Italy 16 564 1.0× 187 0.5× 464 1.3× 124 0.8× 132 1.7× 47 1.1k
Hiroyuki Okabe Japan 16 584 1.0× 297 0.7× 243 0.7× 126 0.8× 89 1.2× 37 850
D. J. Th. Wagener Netherlands 18 506 0.9× 401 1.0× 311 0.9× 236 1.5× 154 2.0× 57 1.1k
Hisanobu Niitani Japan 18 654 1.1× 578 1.4× 358 1.0× 93 0.6× 55 0.7× 65 1.1k
Hideyuki Ohshimo Japan 13 1.0k 1.7× 709 1.7× 284 0.8× 317 2.0× 112 1.5× 17 1.4k
Hiroaki Ozasa Japan 17 730 1.3× 479 1.2× 437 1.3× 92 0.6× 167 2.2× 80 1.1k

Countries citing papers authored by Yuji Shimamoto

Since Specialization
Citations

This map shows the geographic impact of Yuji Shimamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuji Shimamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuji Shimamoto more than expected).

Fields of papers citing papers by Yuji Shimamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuji Shimamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuji Shimamoto. The network helps show where Yuji Shimamoto may publish in the future.

Co-authorship network of co-authors of Yuji Shimamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yuji Shimamoto. A scholar is included among the top collaborators of Yuji Shimamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuji Shimamoto. Yuji Shimamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Shimamoto, Yuji, Mamoru Nukatsuka, Teiji Takechi, & Masakazu Fukushima. (2015). Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. International Journal of Molecular Medicine. 37(2). 319–328. 13 indexed citations
2.
Kazuno, Hiromi, Yuji Shimamoto, Hiroaki Tsujimoto, et al.. (2007). Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil. Oncology Reports. 17(6). 1453–60. 10 indexed citations
3.
Shimamoto, Yuji, Hiromi Kazuno, Yuko Murakami, et al.. (2002). Cellular and Biochemical Mechanisms of the Resistance of Human Cancer Cells to a New Anticancer Ribo‐nucleoside, TAS‐106. Japanese Journal of Cancer Research. 93(4). 445–452. 17 indexed citations
4.
Shimamoto, Yuji, Hiroyuki Okabe, Hiromi Kazuno, et al.. (2002). Sensitivity of Human Cancer Cells to the New Anticancer Ribo‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2. Japanese Journal of Cancer Research. 93(7). 825–833. 48 indexed citations
5.
Shimamoto, Yuji, Akio Fujioka, Hiromi Kazuno, et al.. (2001). Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine. Japanese Journal of Cancer Research. 92(3). 343–351. 19 indexed citations
6.
Shimamoto, Yuji, Atsushi Azuma, Yusuke Wataya, et al.. (2001). Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. International Journal of Molecular Medicine. 8(3). 273–8. 27 indexed citations
7.
Kato, Toshiyuki, Yuji Shimamoto, Junji Uchida, et al.. (2001). Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.. PubMed. 21(3B). 1705–12. 32 indexed citations
8.
Takatori, Satoshi, Hiroshi Kanda, Yusuke Wataya, et al.. (1999). Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3- C -ethynyl-β- D - ribo -pentofuranosyl)cytosine and 1-(3- C -ethynyl-β- D - ribo -pentofuranosyl)uracil. Cancer Chemotherapy and Pharmacology. 44(2). 97–104. 55 indexed citations
9.
Fukushima, Masakazu, Yuji Shimamoto, Toshiyuki Kato, et al.. (1998). Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anti-Cancer Drugs. 9(9). 817–823. 43 indexed citations
10.
Shirasaka, Tetsuhiko, Yuji Shimamoto, Toshiyuki Kato, & M Fukushima. (1998). [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].. PubMed. 25(3). 371–84. 8 indexed citations
11.
Hattori, Hideshi, Tomoharu Iino, Yuichi Yoshimura, et al.. (1998). Nucleosides and Nucleotides. 175. Structural Requirements of the Sugar Moiety for the Antitumor Activities of New Nucleoside Antimetabolites, 1-(3-C-Ethynyl-β-d-ribo-pentofuranosyl)cytosine and -uracil. Journal of Medicinal Chemistry. 41(15). 2892–2902. 49 indexed citations
12.
Fukushima, M, Hirofumi Satake, Junji Uchida, et al.. (1998). Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.. International Journal of Oncology. 13(4). 693–8. 95 indexed citations
13.
Shirasaka, Tetsuhiko, Yuji Shimamoto, Hideyuki Ohshimo, Hiroko Saito, & Masakazu Fukushima. (1993). Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemotherapy and Pharmacology. 32(3). 167–172. 127 indexed citations
14.
Shirasaka, Tetsuhiko, Yuji Shimamoto, & Masakazu Fukushima. (1993). Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.. PubMed. 53(17). 4004–9. 326 indexed citations
15.
Shirasaka, Tetsuhiko, Yuji Shimamoto, Hideyuki Ohshimo, Akiko Kimura, & M Fukushima. (1991). [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil].. PubMed. 18(3). 403–9. 12 indexed citations
16.
Shirasaka, Tetsuhiko, M Fukushima, Yuji Shimamoto, et al.. (1990). [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].. PubMed. 17(5). 1051–8. 5 indexed citations
17.
Fujii, Setsuro, Masakazu Fukushima, Yuji Shimamoto, et al.. (1989). Antitumor Activity of BOF‐A2, a New 5‐Fluorouracil Derivative. Japanese Journal of Cancer Research. 80(2). 173–181. 23 indexed citations
18.
Fukushima, Masakazu, et al.. (1989). Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil. Japanese Journal of Cancer Research. 80(6). 509–512. 8 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C.J.A. van Moorsel Breakdown of academic impact, for papers by Daphne Voorn Breakdown of academic impact, for papers by Fumio Nakagawa Breakdown of academic impact, for papers by Hoo G. Chun Breakdown of academic impact, for papers by Giovanni Codacci-Pisanelli Breakdown of academic impact, for papers by Hiroyuki Okabe Breakdown of academic impact, for papers by D. J. Th. Wagener Breakdown of academic impact, for papers by Hisanobu Niitani Breakdown of academic impact, for papers by Hideyuki Ohshimo Breakdown of academic impact, for papers by Hiroaki Ozasa
Rankless by CCL
2026